Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Tiziana Life Sciences Ltd

TLSA ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.14

▲ +9.13%

Market Cap $144.44M · Vol 239.51K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$144.44M

Micro Cap

Div Yield

N/A

EPS Growth

+0.00%

YoY

RSI (14)

75.67

Momentum

Beta

0.20

vs Market

52W High

$2.33

51.18% below

52W Low

$0.87

31.02% above

Volume

239.51K

Avg 147.85K

P/B

3,453.00

Price-to-book

ROE

N/A

Return on equity

Free Float

52.35%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Tiziana Life Sciences Ltd (TLSA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TLSA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+13.50%

-8.47%

-21.72%

-18.35%

YTD

-23.83%

-43.25%

+37.99%

-67.01%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-18,431,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-161.82% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3,453.00
P/FCF	N/A
EPS Growth	+0.00%
Outstanding Shares	127.26M

Technical Indicators

50-Day SMA	$1.11
200-Day SMA	$1.39
RSI (14)	75.67
Beta	0.20
52-Week High	$2.33
52-Week Low	$0.87

Volume Today	239.51K
Avg Daily Volume (30D)	147.85K
Relative Volume	1.62x
Volatility (10D)	60.78
Volatility (30D)	89.39
Free Float	52.35%

Analyst Consensus

BUY

Current Price $1.14

Mean Target $9.00

52W Low$0.87 52W High$2.33

Current

Target

$0.87 $2.33

Current Analyst target

+692.95% upside potential · 1 analysts

Identifiers

ExchangeNasdaq

FIGIBBG0129Q42Y1

ISINBMG889121031

CountryUnited Kingdom

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Tiziana Life Sciences Ltd. is a biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Its clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer’s, and Amyotrophic lateral sclerosis. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.